5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug

Retatrutide hasn’t been approved by the FDA, hasn’t been priced, and doesn’t have a brand name yet — but it already carries the nickname “the trillion-dollar drug.” In a roundup published August 14, The American Journal of Managed Care (AJMC) distills five things payers, clinicians, and health systems should know now, before the drug reaches the market (AJMC) — a primer with direct relevance for Canadian payers and patients planning around a potential approval in 2027.

Unprecedented trial results

Across multiple Phase 3 trials, retatrutide’s triple-hormone mechanism (GIP/GLP-1/glucagon) has produced substantial, dose-dependent weight loss. In TRIUMPH-1, adults with obesity achieved 28.3% weight loss at 80 weeks and 30.3% at 104 weeks — matching bariatric-surgery levels. In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes lost up to 49.6 lbs (20.8%) at 80 weeks, and in TRIUMPH-3, adults with severe obesity and established cardiovascular disease lost up to 55.8 lbs (22.6%) at 80 weeks (AJMC). A dedicated diabetes study, TRANSCEND-T2D-1, showed a 2.0-point HbA1c reduction alongside 16.8% weight loss. Retatrutide also lowered triglycerides, non-HDL cholesterol, and systolic blood pressure relative to placebo in data presented at the ADA 2026 Scientific Sessions.

The “trillion-dollar” label: hype rooted in real numbers

The nickname has been attributed to Stanford neuroscientist and podcaster Andrew Huberman, who called retatrutide “a trillion-dollar drug” during a 2026 interview. Taken literally, no drug has ever generated $1 trillion in annual sales — analyst projections are far more modest, with some estimates approaching $15 billion annually within several years of launch. Still, the label reflects genuine commercial enthusiasm: Evaluate ranked retatrutide as the pharmaceutical industry’s highest net-present-value pipeline asset in January 2026 at roughly $29 billion, and Eli Lilly became the first pharmaceutical company to surpass a $1 trillion market capitalization in 2025 (Yahoo Finance).

An expanding gray market

Lilly reported first-quarter 2026 revenue of $19.8 billion, up 56% year over year, with tirzepatide sales (Mounjaro, Zepbound) up 125% and 80% — and industry publication Fitt Insider has identified retatrutide as Lilly’s leading next-generation obesity therapy. Outside regulated channels, however, a parallel market has emerged: vendors sell vials labeled as “research chemicals” and “not for human consumption,” yet some consumers report self-administering the drug using dosing advice shared on social media and online forums. The FDA has issued warning letters to firms marketing unapproved GLP-1–related products, including products represented as retatrutide, for human use, citing violations of the Federal Food, Drug, and Cosmetic Act (AJMC). This is the same phenomenon behind Eli Lilly’s six black-market lawsuits filed on August 12 — and the same trade Canadian authorities have repeatedly warned consumers against.

A legal fight over “biologic” status

Since September 2024, Lilly and the FDA have been in litigation over whether retatrutide qualifies as a biologic. The distinction matters commercially: a Biologics License Application (BLA) confers 12 years of reference-product exclusivity, versus five years for a qualifying New Drug Application (NDA). Courts have issued a mixed ruling — vacating the FDA’s determination while returning the question of whether the molecule is “analogous to a protein” to the agency — and Lilly has appealed while continuing to pursue the BLA pathway (BioSpace). The outcome could shape both review timing and exclusivity, with knock-on effects for when biosimilar competition might eventually reach Canada.

The Q1 2027 filing clock

Lilly plans to submit its first regulatory application in the first quarter of 2027, initially seeking indications for obesity, obstructive sleep apnea, and knee osteoarthritis pain. The filing depends on more than clinical data: the unresolved BLA-vs-NDA dispute could influence both review and exclusivity, and gray-market demand means clinicians, health systems, and payers may already be seeing patients who used unapproved versions of the drug before any regulatory decision (AJMC).

Canadian context

AJMC’s primer is written for U.S. managed care, but the planning pressure applies in Canada as well. A U.S. filing in Q1 2027 points to Health Canada review following by months — potentially a Canadian decision in late 2027 or early 2028 — leaving provincial formulary committees and payers a narrow window to prepare for a therapy that may target obesity, sleep apnea, and knee osteoarthritis pain simultaneously. The U.S. biologic classification fight matters here too: a longer U.S. exclusivity period for a biologic would delay biosimilar entry, shaping the pricing environment Canadian public and private payers will eventually face.

On safety: retatrutide remains an investigational drug not approved by Health Canada or the FDA, and no legitimate version exists for sale anywhere. Canadians should avoid products sold online as “research chemicals” or “not for human consumption,” report suspicious sellers to Health Canada, and rely on approved treatments, legitimate clinical trial enrollment, or the Special Access Programme.